The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma
作者: Rana R. McKayPeter VuLaurence K. AlbigesXun LinRonit SimantovJennifer S. TemelToni K. Choueiri
作者单位: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Division of Hematology/Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA
3Department of Cancer Medicine, Institute Gustave Roussy, Paris, France
4Pfizer Oncology, Pfizer Inc, New York, NY
5Department of Medicine, Massachusetts General Hospital, Boston, MA
刊名: Clinical Genitourinary Cancer, 2019, Vol.17 (6), pp.443-450.e1
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2019.07.004
关键词: PrognosisRenal cell carcinomaSurvivalTargeted therapyWeight loss
英文摘要: Abstract(#br)Background(#br)The relationship between weight change during treatment and survival remains poorly characterized in patients with metastatic renal cell carcinoma (mRCC).(#br)Patients and Methods(#br)In this retrospective analysis we included 3311 patients with mRCC treated in phase II/III first-line or second-line targeted therapy clinical trials and assessed the effect of weight change on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) at 6 and 12 weeks from treatment initiation. Weight change was defined as weight loss (≥5% reduction), weight gain (≥2% increase), or stable weight from baseline. Survival analyses were performed using the Kaplan–Meier method and adjusted for known prognostic factors using Cox regression multivariable...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:1.429 (2012)

×